BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gilad Y, Firer M, Gellerman G. Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. Biomedicines 2016;4:E11. [PMID: 28536378 DOI: 10.3390/biomedicines4020011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Patsenker L, Gellerman G. Fluorescent Reporters for Drug Delivery Monitoring. Isr J Chem 2020;60:504-18. [DOI: 10.1002/ijch.201900137] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Luan X, Wu Y, Shen YW, Zhang H, Zhou YD, Chen HZ, Nagle DG, Zhang WD. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat Prod Rep 2021;38:7-17. [PMID: 32776055 DOI: 10.1039/d0np00019a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Urbaniak T, Musiał W. Selected Physicochemical and Pharmaceutical Properties of Poly-ε-caprolactone and Poly(d,l-lactide-co-ε-caprolactone) Conjugates of Lamivudine Synthesized via Ring-Opening Polymerization. Polymers (Basel) 2019;11:E2124. [PMID: 31861191 DOI: 10.3390/polym11122124] [Reference Citation Analysis]
4 Zarei O, Benvenuti S, Ustun-alkan F, Hamzeh-mivehroud M, Dastmalchi S. Identification of a RON tyrosine kinase receptor binding peptide using phage display technique and computational modeling of its binding mode. J Mol Model 2017;23. [DOI: 10.1007/s00894-017-3437-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Kalishwaralal K, Luboshits G, Firer MA. Synthesis of Gold Nanoparticle: Peptide-Drug Conjugates for Targeted Drug Delivery. Methods Mol Biol 2020;2059:145-54. [PMID: 31435919 DOI: 10.1007/978-1-4939-9798-5_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
6 Kiss K, Biri-Kovács B, Szabó R, Ranđelović I, Enyedi KN, Schlosser G, Orosz Á, Kapuvári B, Tóvári J, Mező G. Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems. Eur J Med Chem 2019;176:105-16. [PMID: 31100648 DOI: 10.1016/j.ejmech.2019.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Sheard DE, Li W, O’brien-simpson NM, Separovic F, Wade JD. Peptide Multimerization as Leads for Therapeutic Development. Biologics 2022;2:15-44. [DOI: 10.3390/biologics2010002] [Reference Citation Analysis]
8 Tian R, Zhu L, Qin Z, Wang G, Wang J, Zhang H. Glypican-3 (GPC3) targeted Fe3O4 core/Au shell nanocomplex for fluorescence/MRI/photoacoustic imaging-guided tumor photothermal therapy. Biomater Sci 2019;7:5258-69. [PMID: 31603456 DOI: 10.1039/c9bm01248f] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
9 Nouri K, Azad T, Ling M, Janse van Rensburg HJ, Pipchuk A, Shen H, Hao Y, Zhang J, Yang X. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors. Cancers (Basel) 2019;11:E1596. [PMID: 31635084 DOI: 10.3390/cancers11101596] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
10 Wang SH, Yu J. Structure-based design for binding peptides in anti-cancer therapy. Biomaterials 2018;156:1-15. [PMID: 29182932 DOI: 10.1016/j.biomaterials.2017.11.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
11 Silva JV, Santos SDS, Machini MT, Giarolla J. Neglected tropical diseases and infectious illnesses: potential targeted peptides employed as hits compounds in drug design. J Drug Target 2021;29:269-83. [PMID: 33059502 DOI: 10.1080/1061186X.2020.1837843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kalimuthu K, Lubin BC, Bazylevich A, Gellerman G, Shpilberg O, Luboshits G, Firer MA. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells. J Nanobiotechnology 2018;16:34. [PMID: 29602308 DOI: 10.1186/s12951-018-0362-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
13 Alqaraghuli HGJ, Kashanian S, Rafipour R. A Review on Targeting Nanoparticles for Breast Cancer. Curr Pharm Biotechnol 2019;20:1087-107. [PMID: 31364513 DOI: 10.2174/1389201020666190731130001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
14 Mocanu CS, Drochioiu G. The Interaction of Possible Anti-AD ASA-NAP Peptide Conjugate with Tubulin: A Theoretical and Experimental Insight. Int J Pept Res Ther 2021;27:2487-503. [DOI: 10.1007/s10989-021-10267-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Barrabés S, Ng-Choi I, Martínez MÁ, Manzano BR, Jalón FA, Espino G, Feliu L, Planas M, de Llorens R, Massaguer A. A nucleus-directed bombesin derivative for targeted delivery of metallodrugs to cancer cells. J Inorg Biochem 2020;212:111214. [PMID: 32919249 DOI: 10.1016/j.jinorgbio.2020.111214] [Reference Citation Analysis]
16 Kostrzewa T, Sahu KK, Gorska-Ponikowska M, Tuszynski JA, Kuban-Jankowska A. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2. Drug Des Devel Ther 2018;12:4139-47. [PMID: 30584278 DOI: 10.2147/DDDT.S186614] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Furman O, Zaporozhets A, Tobi D, Bazylevich A, Firer MA, Patsenker L, Gellerman G, Lubin BCR. Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery. Pharmaceutics 2022;14:1505. [DOI: 10.3390/pharmaceutics14071505] [Reference Citation Analysis]
18 Jacquot G, Lécorché P, Malcor JD, Laurencin M, Smirnova M, Varini K, Malicet C, Gassiot F, Abouzid K, Faucon A, David M, Gaudin N, Masse M, Ferracci G, Dive V, Cisternino S, Khrestchatisky M. Optimization and in Vivo Validation of Peptide Vectors Targeting the LDL Receptor. Mol Pharm 2016;13:4094-105. [PMID: 27656777 DOI: 10.1021/acs.molpharmaceut.6b00687] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Conibear AC, Schmid A, Kamalov M, Becker CFW, Bello C. Recent Advances in Peptide-Based Approaches for Cancer Treatment. Curr Med Chem 2020;27:1174-205. [PMID: 29173146 DOI: 10.2174/0929867325666171123204851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
20 Sengee M, Eksteen JJ, Nergård SL, Vasskog T, Sydnes LK. Preparation and Assessment of Self-Immolative Linkers for Therapeutic Bioconjugates with Amino- and Hydroxyl-Containing Cargoes. Bioconjugate Chem 2019;30:1489-99. [DOI: 10.1021/acs.bioconjchem.9b00214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Maheshwari N, Tekade M, Soni N, Ghode P, Sharma MC, Deb PK, Tekade RK. Functionalized Carbon Nanotubes for Protein, Peptide, and Gene Delivery. Biomaterials and Bionanotechnology. Elsevier; 2019. pp. 613-37. [DOI: 10.1016/b978-0-12-814427-5.00016-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Shahin-Kaleybar B, Niazi A, Afsharifar A, Nematzadeh G, Yousefi R, Retzl B, Hellinger R, Muratspahić E, Gruber CW. Isolation of Cysteine-Rich Peptides from Citrullus colocynthis. Biomolecules 2020;10:E1326. [PMID: 32948080 DOI: 10.3390/biom10091326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Fisher E, Pavlenko K, Vlasov A, Ramenskaya G. Peptide-Based Therapeutics for Oncology. Pharmaceut Med 2019;33:9-20. [PMID: 31933267 DOI: 10.1007/s40290-018-0261-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Okoh OA, Klahn P. Trimethyl Lock: A Multifunctional Molecular Tool for Drug Delivery, Cellular Imaging, and Stimuli-Responsive Materials. ChemBioChem 2018;19:1668-94. [DOI: 10.1002/cbic.201800269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
25 Farshbaf M, Valizadeh H, Panahi Y, Fatahi Y, Chen M, Zarebkohan A, Gao H. The impact of protein corona on the biological behavior of targeting nanomedicines. Int J Pharm 2022;614:121458. [PMID: 35017025 DOI: 10.1016/j.ijpharm.2022.121458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
26 Gilad Y, Gellerman G, Lonard DM, O'Malley BW. Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations. Cancers (Basel) 2021;13:669. [PMID: 33562300 DOI: 10.3390/cancers13040669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Konkankit CC, Marker SC, Knopf KM, Wilson JJ. Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. Dalton Trans 2018;47:9934-74. [DOI: 10.1039/c8dt01858h] [Cited by in Crossref: 106] [Cited by in F6Publishing: 22] [Article Influence: 26.5] [Reference Citation Analysis]
28 Li S, Zhao H, Fan Y, Zhao G, Wang R, Wen F, Wang J, Wang X, Wang Y, Gao Y. Design, synthesis, and in vitro antitumor activity of a transferrin receptor-targeted peptide-doxorubicin conjugate. Chem Biol Drug Des 2020;95:58-65. [PMID: 31452330 DOI: 10.1111/cbdd.13613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Bar-zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. Drug Resistance Updates 2017;31:15-30. [DOI: 10.1016/j.drup.2017.05.002] [Cited by in Crossref: 146] [Cited by in F6Publishing: 131] [Article Influence: 29.2] [Reference Citation Analysis]
30 Murányi J, Varga A, Gurbi B, Gyulavári P, Mező G, Vántus T. In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues. J Vis Exp 2017. [PMID: 28362408 DOI: 10.3791/55529] [Reference Citation Analysis]
31 Wang CY, Lin BL, Chen CH. Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3. Cancer Biol Ther 2021;22:12-8. [PMID: 33249980 DOI: 10.1080/15384047.2020.1833156] [Reference Citation Analysis]
32 Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
33 Gerbelli BB, Vassiliades SV, Rojas JEU, Pelin JNBD, Mancini RSN, Pereira WSG, Aguilar AM, Venanzi M, Cavalieri F, Giuntini F, Alves WA. Hierarchical Self‐Assembly of Peptides and its Applications in Bionanotechnology. Macromol Chem Phys 2019;220:1900085. [DOI: 10.1002/macp.201900085] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
34 Corrigan AM, Karlsson J, Wildenhain J, Knerr L, Ölwegård-Halvarsson M, Karlsson M, Lünse S, Wang Y. IA-Lab: A MATLAB framework for efficient microscopy image analysis development, applied to quantifying intracellular transport of internalized peptide-drug conjugate. PLoS One 2019;14:e0220627. [PMID: 31369634 DOI: 10.1371/journal.pone.0220627] [Reference Citation Analysis]
35 Vrettos EI, Mező G, Tzakos AG. On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein J Org Chem 2018;14:930-54. [PMID: 29765474 DOI: 10.3762/bjoc.14.80] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
36 Alavi SE, Cabot PJ, Moyle PM. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Mol Pharm 2019;16:2278-95. [PMID: 31050435 DOI: 10.1021/acs.molpharmaceut.9b00308] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
37 Sahu BP, Baishya R, Hatiboruah JL, Laloo D, Biswas N. A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches. J Pharm Investig . [DOI: 10.1007/s40005-022-00583-x] [Reference Citation Analysis]
38 Rozovsky A, Ebaston TM, Zaporozhets A, Bazylevich A, Tuchinsky H, Patsenker L, Gellerman G. Theranostic system for ratiometric fluorescence monitoring of peptide-guided targeted drug delivery. RSC Adv 2019;9:32656-64. [DOI: 10.1039/c9ra06334j] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
39 Pryyma A, Matinkhoo K, Bu YJ, Merkens H, Zhang Z, Bénard F, Perrin DM. Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells. RSC Chem Biol 2022;3:69-78. [DOI: 10.1039/d1cb00036e] [Reference Citation Analysis]
40 Roveri M, Bernasconi M, Leroux J, Luciani P. Peptides for tumor-specific drug targeting: state of the art and beyond. J Mater Chem B 2017;5:4348-64. [DOI: 10.1039/c7tb00318h] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
41 Kim MW, Kwon SH, Choi JH, Lee A. A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy. Int J Mol Sci 2018;19:E3859. [PMID: 30518027 DOI: 10.3390/ijms19123859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
42 He R, Finan B, Mayer JP, DiMarchi RD. Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules 2019;24:E1855. [PMID: 31091786 DOI: 10.3390/molecules24101855] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
43 Kwak MH, Yi G, Yang SM, Choe Y, Choi S, Lee HS, Kim E, Lim YB, Na K, Choi MG, Koo H, Park JM. A Dodecapeptide Selected by Phage Display as a Potential Theranostic Probe for Colon Cancers. Transl Oncol 2020;13:100798. [PMID: 32454443 DOI: 10.1016/j.tranon.2020.100798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Karpiński TM, Adamczak A. Anticancer Activity of Bacterial Proteins and Peptides. Pharmaceutics 2018;10:E54. [PMID: 29710857 DOI: 10.3390/pharmaceutics10020054] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
45 Kufka R, Rennert R, Kaluđerović GN, Weber L, Richter W, Wessjohann LA. Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells. Beilstein J Org Chem 2019;15:96-105. [PMID: 30680044 DOI: 10.3762/bjoc.15.11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
46 Pietersz GA, Wang X, Yap ML, Lim B, Peter K. Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies. Nanomedicine (Lond) 2017;12:1873-89. [PMID: 28703636 DOI: 10.2217/nnm-2017-0043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
47 Ahmad E, Ali A, Fatima MT, Nimisha, Apurva, Kumar A, Sumi MP, Sattar RSA, Mahajan B, Saluja SS. Ligand decorated biodegradable nanomedicine in the treatment of cancer. Pharmacol Res 2021;167:105544. [PMID: 33722711 DOI: 10.1016/j.phrs.2021.105544] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Conibear AC, Hager S, Mayr J, Klose MHM, Keppler BK, Kowol CR, Heffeter P, Becker CFW. Multifunctional αvβ6 Integrin-Specific Peptide-Pt(IV) Conjugates for Cancer Cell Targeting. Bioconjug Chem 2017;28:2429-39. [PMID: 28796473 DOI: 10.1021/acs.bioconjchem.7b00421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
49 Uddin MZ, Li X, Joo H, Tsai J, Wrischnik L, Jasti B. Rational Design of Peptide Ligands Based on Knob–Socket Protein Packing Model Using CD13 as a Prototype Receptor. ACS Omega 2019;4:5126-36. [DOI: 10.1021/acsomega.8b03421] [Reference Citation Analysis]
50 Kulkarni N, Shinde SD, Jadhav GS, Adsare DR, Rao K, Kachhia M, Maingle M, Patil SP, Arya N, Sahu B. Peptide-Chitosan Engineered Scaffolds for Biomedical Applications. Bioconjug Chem 2021;32:448-65. [PMID: 33656319 DOI: 10.1021/acs.bioconjchem.1c00014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Li S, Zhao H, Mao X, Fan Y, Liang X, Wang R, Xiao L, Wang J, Liu Q, Zhao G. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate. Pharm Res 2019;36. [DOI: 10.1007/s11095-019-2688-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
52 Tjandra KC, Mccarthy N, Yang L, Laos AJ, Sharbeen G, Phillips PA, Forgham H, Sagnella SM, Whan RM, Kavallaris M, Thordarson P, Mccarroll JA. Identification of Novel Medulloblastoma Cell-Targeting Peptides for Use in Selective Chemotherapy Drug Delivery. J Med Chem 2020;63:2181-93. [DOI: 10.1021/acs.jmedchem.9b00851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
53 Sakamoto K, Shinohara T, Adachi Y, Asami T, Ohtaki T. A novel LRP1-binding peptide L57 that crosses the blood brain barrier. Biochem Biophys Rep 2017;12:135-9. [PMID: 29090274 DOI: 10.1016/j.bbrep.2017.07.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
54 Ragozin E, Hesin A, Bazylevich A, Tuchinsky H, Bovina A, Shekhter Zahavi T, Oron-herman M, Kostenich G, Firer M, Rubinek T, Wolf I, Luboshits G, Sherman M, Gellerman G. New somatostatin-drug conjugates for effective targeting pancreatic cancer. Bioorganic & Medicinal Chemistry 2018;26:3825-36. [DOI: 10.1016/j.bmc.2018.06.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]